Last reviewed · How we verify
DR-103
DR-103 is a medication used to treat a specific condition by targeting a particular biological pathway.
DR-103 is a medication used to treat a specific condition by targeting a particular biological pathway. Used for Treatment of moderate to severe vasomotor symptoms associated with menopause.
At a glance
| Generic name | DR-103 |
|---|---|
| Also known as | levonorgestrel/ethinyl estradiol, Quartette® |
| Sponsor | Teva Women's Health |
| Drug class | Selective estrogen receptor modulator |
| Target | Estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Women's Health |
| Phase | Phase 3 |
Mechanism of action
DR-103 works by binding to a specific receptor, which leads to a cascade of downstream effects that ultimately result in the desired therapeutic outcome. This mechanism of action is unique compared to other medications in its class.
Approved indications
- Treatment of moderate to severe vasomotor symptoms associated with menopause
Common side effects
- Hot flashes
- Vaginal discharge
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DR-103 CI brief — competitive landscape report
- DR-103 updates RSS · CI watch RSS
- Teva Women's Health portfolio CI